Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
Fiche publication
Date publication
mai 2021
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Coiro S, Girerd N, McMurray JJV, Pitt B, Swedberg K, van Veldhuisen DJ, Lamiral Z, Rossignol P, Zannad F
Lien Pubmed
Résumé
Loop diuretics are the mainstay of congestion treatment in patients with heart failure (HF). We assessed the association between baseline loop diuretic use and outcome. We also compared the increment in risk related to diuretic dose with conventional prognostic enrichment criteria used in the EMPHASIS-HF trial, which included patients with systolic HF and mild symptoms, such as prior hospitalization and elevated natriuretic peptides.
Mots clés
Eplerenone, Heart failure hospitalization, Heart failure with reduced ejection faction, Loop diuretics, Prognostic enrichment criteria
Référence
Clin Res Cardiol. 2021 May 6;: